{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:33Z","timestamp":1793661033125,"version":"4.5.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.annonc.2021.10.009","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T16:36:05Z","timestamp":1635179765000},"page":"193-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Phase II study of ceralasertib (AZD6738) in combination with durvalumab in\u00a0patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy"],"prefix":"10.1016","volume":"33","author":[{"given":"R.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.T.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Loemb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.S.","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Armenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lukashchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.-Y.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.annonc.2021.10.009_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"10.1016\/j.annonc.2021.10.009_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.009_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.suc.2019.09.009","article-title":"Principles of immunotherapy in melanoma","volume":"100","author":"Onitilo","year":"2020","journal-title":"Surg Clin North Am"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.009_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2021.10.009_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.annonc.2021.10.009_bib6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.10.009_bib7","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2016.34.15_suppl.9503","article-title":"Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"34","author":"Robert","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.10.009_bib8","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1200\/JCO.2016.34.15_suppl.4538","article-title":"Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs)","volume":"34","author":"McBride","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.annonc.2021.10.009_bib9","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/JCO.2017.35.6_suppl.300","article-title":"DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC)","volume":"35","author":"Galsky","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.009_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-019-0784-8","article-title":"Prospects for combining immune checkpoint blockade with PARP inhibition","volume":"12","author":"Li","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.10.009_bib11","doi-asserted-by":"crossref","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7","key":"10.1016\/j.annonc.2021.10.009_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4155\/fmc.15.33","article-title":"Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer","volume":"7","author":"Foote","year":"2015","journal-title":"Future Med Chem"},{"issue":"22","key":"10.1016\/j.annonc.2021.10.009_bib13","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.annonc.2021.10.009_bib14","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1158\/1078-0432.CCR-21-0251","article-title":"Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.annonc.2021.10.009_bib15","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"9","key":"10.1016\/j.annonc.2021.10.009_bib16","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"issue":"3","key":"10.1016\/j.annonc.2021.10.009_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.009_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.009_bib19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"7571","key":"10.1016\/j.annonc.2021.10.009_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A\u00a0global reference for human genetic variation","volume":"526","author":"Genomes Project","year":"2015","journal-title":"Nature"},{"issue":"7311","key":"10.1016\/j.annonc.2021.10.009_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nature09298","article-title":"Integrating common and rare genetic variation in diverse human populations","volume":"467","author":"Altshuler","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.009_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"key":"10.1016\/j.annonc.2021.10.009_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13059-016-0893-4","article-title":"DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution","volume":"17","author":"Rosenthal","year":"2016","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.009_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.annonc.2021.10.009_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"issue":"7269","key":"10.1016\/j.annonc.2021.10.009_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.annonc.2021.10.009_bib27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.annonc.2021.10.009_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","article-title":"Comprehensive characterization of cancer driver genes and mutations","volume":"173","author":"Bailey","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.009_bib29","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/s41467-020-15912-7","article-title":"Mutational signatures are jointly shaped by DNA damage and repair","volume":"11","author":"Volkova","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.009_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney Michael","year":"2015","journal-title":"Cell"},{"issue":"6282","key":"10.1016\/j.annonc.2021.10.009_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.annonc.2021.10.009_bib32","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.009_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","article-title":"Gene expression markers of tumor infiltrating leukocytes","volume":"5","author":"Danaher","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"26","key":"10.1016\/j.annonc.2021.10.009_bib34","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2021.10.009_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2017.376","article-title":"Combining DNA damaging therapeutics with immunotherapy: more haste, less speed","volume":"118","author":"Brown","year":"2018","journal-title":"Br J Cancer"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.10.009_bib36","doi-asserted-by":"crossref","first-page":"10006","DOI":"10.1200\/JCO.2020.38.15_suppl.10006","article-title":"Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies","volume":"38","author":"Sarnaik","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.10.009_bib37","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1200\/JCO.2021.39.15_suppl.9504","article-title":"Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: updated findings of LEAP-004","volume":"39","author":"Arance","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.10.009_bib38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.seminoncol.2015.05.011","article-title":"The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment","volume":"42","author":"Gajewski","year":"2015","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.009_bib39","doi-asserted-by":"crossref","first-page":"e000398","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421045452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421045452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:07:00Z","timestamp":1760335620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421045452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0923753421045452"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.10.009","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in\u00a0patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}